Article Correctness Is Author's Responsibility: CAR-T therapy for lymphoma studied at UNC Lineberger receives FDA fast-track designation

(UNC Lineberger Comprehensive Cancer Center) Based on proof-of-concept results from clinical trials at University of North Carolina Lineberger Comprehensive Cancer Center and Baylor College of Medicine, an investigational cellular immunotherapy for Hodgkin lymphoma has received a Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration.